Gilman Hill Asset Management LLC lessened its holdings in shares of Pfizer (NYSE:PFE) by 1.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 133,790 shares of the biopharmaceutical company’s stock after selling 1,900 shares during the quarter. Pfizer accounts for about 2.0% of Gilman Hill Asset Management LLC’s portfolio, making the stock its 16th largest position. Gilman Hill Asset Management LLC’s holdings in Pfizer were worth $4,846,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. Beach Investment Management LLC. purchased a new stake in shares of Pfizer in the second quarter valued at approximately $5,214,000. Hanson McClain Inc. boosted its holdings in shares of Pfizer by 2.0% in the second quarter. Hanson McClain Inc. now owns 13,898 shares of the biopharmaceutical company’s stock valued at $467,000 after purchasing an additional 276 shares during the period. Alpha Omega Wealth Management LLC boosted its holdings in shares of Pfizer by 3.4% in the second quarter. Alpha Omega Wealth Management LLC now owns 108,815 shares of the biopharmaceutical company’s stock valued at $3,655,000 after purchasing an additional 3,534 shares during the period. Usca Ria LLC boosted its holdings in shares of Pfizer by 0.3% in the second quarter. Usca Ria LLC now owns 332,964 shares of the biopharmaceutical company’s stock valued at $11,184,000 after purchasing an additional 1,033 shares during the period. Finally, Intrust Bank NA boosted its holdings in shares of Pfizer by 2.5% in the second quarter. Intrust Bank NA now owns 65,268 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 1,596 shares during the period. Institutional investors and hedge funds own 71.20% of the company’s stock.
A number of analysts recently issued reports on the company. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday. Barclays lowered Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $41.00 to $38.00 in a report on Thursday. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, April 2nd. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the stock a “hold” rating in a research note on Monday, February 26th. Finally, Credit Suisse Group boosted their price objective on shares of Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $39.25.
Shares of PFE stock opened at $35.17 on Friday. The firm has a market cap of $215,077.02, a PE ratio of 13.27, a price-to-earnings-growth ratio of 1.80 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer has a 12-month low of $31.67 and a 12-month high of $39.43.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.47 earnings per share. analysts predict that Pfizer will post 2.96 earnings per share for the current year.
Pfizer declared that its Board of Directors has initiated a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.
In other news, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/pfizer-pfe-holdings-lessened-by-gilman-hill-asset-management-llc.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.